Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Nat Rev Cancer. 2015 Jan;15(1):7–24. doi: 10.1038/nrc3860

Table 2. Pan-PI3K inhibitors and their clinical applications.

Agent Company Target Trial stage* Tumor types*
BKM120 Novartis Class I PI3Ks I, II, and III

  • NSCLC

  • Endometrial

  • Thyroid

  • CRPC

  • Breast

  • Colorectal

  • Head and neck

  • GBM

  • Renal cell

  • B cell lymphoma

  • GIST

  • Melanoma

  • Ovarian

  • Prostate

  • Pancreatic

  • Leukemia

  • Esophageal

  • Cervical

  • Non-Hodgkin lymphoma

  • Squamous NSCLC

  • Adv. solid tumors
GDC0941 Genentech Class I PI3Ks I and II

  • Breast

  • NSCLC

  • Non-Hodgkin lymphoma

  • Adv. solid tumors
BAY80-6946 Bayer Class I PI3Ks I and II

  • Non-Hodgkin lymphoma

  • Adv. solid tumors
ZSTK474 Zenyaku Kogyo Co. Class I PI3Ks I and II

  • Adv.solid tumors
PX866 Oncothyreon Class I PI3Ks I and II

  • Colorectal

  • SCCHN

  • Melanoma

  • NSCLC

  • Prostate

  • GBM

  • Adv. solid tumors
XL147 Exelixis/Sanofi-Aventis Class I PI3Ks I and II

  • Breast

  • Endometrial

  • Ovarian

  • Lymphoma

  • GBM

  • NSCLC

  • Adv. solid tumors
CH5132799 Chugai Pharma Europe Class I PI3Ks I

  • Adv. solid tumors
*

Data taken from an April 2014 search of http://www.clinicaltrials.gov.

NSCLC, non-small cell lung carcinoma; CRPC, castration-resistant prostate cancer; GIST, gastrointestinal stromal tumor; SCCHN, squamous cell carcinoma of the head and neck; GBM, glioblastoma multiforme